Treatment with loratadine/pseudoephedrine resulted in a mean improvement in CSA1 measurements of 0.
During loratadine/pseudoephedrine treatment, the mean redness score improved by 1.
The difference in mean nasal symptom scores before and after loratadine/pseudoephedrine treatment was 0.
32) points during loratadine/pseudoephedrine therapy.
77) points after loratadine/pseudoephedrine treatment, but the difference was not clinically important or statistically significant.
The patients' quality of sleep appeared to worsen slightly after loratadine/pseudoephedrine treatment, as the mean score fell 0.
The increase in the mean emotional status score after loratadine/pseudoephedrine treatment was 0.
Our results show that loratadine/pseudoephedrine treatment increased nasal cross-sectional area and nasal volume, whereas the effects of placebo were inconsistent, with a slight decrease in the mean CSA1, CSA2, and nasal volume measurements and a very slight mean increase in the CSA3 measurement.
12-14] Our results show that loratadine/pseudoephedrine treatment alleviated redness and edema in the inferior turbinates, decreased the amount of nasal secretions, and improved the overall appearance of the nose.
9] Applying this formula to our results, we found that treatment with loratadine/pseudoephedrine was associated with an improvement in nasal and eye symptoms, both of which were clinically important.